[Therapeutic Strategies Targeting HER2 for Gastric Cancer]
1Dept. of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, The University of Tokyo.
Abstract:
HER2-positive gastric cancer accounts for 30-40% of gastric cancer patients. Since the ToGA trial, trastuzumab has become the mainstay of first-line therapy for HER2-positive gastric cancer over the past decade. Antibody-drug conjugate (ADC)has created a new treatment option recently. The combination and sequence of these anti-HER2 agents with the immune checkpoint inhibitors is reported to be promising. In this article, we review the major clinical trials and discuss the prospects and challenges of treatment strategy for HER2-positive gastric cancer.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Mitogens and the Cell Cycle
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
